Clivatuzumab tetraxetan
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Clivatuzumab tetraxetan
- clivatucyn
- Clivatucyn
- clivatuzumab tetraxetan
- Clivatuzumab tetraxetan
- clivatuzumab tetraxetan [INN]
- CLIVATUZUMAB TETRAXETAN [USAN]
- clivatuzumab tetraxetan inn
- clivatuzumab tetraxetan usan
- hpam 4
- HPAM-4
- hpam4
- hPAM4
- igg dota
- IgG-DOTA
- immu 107
- IMMU-107
- immunoglobulin g1 anti mucin human mus musculus monoclonal hpam4 heavy chain disulfide with human mus musculus monoclonal hpam4 kappa chain dimer 1 4 7 10 tetraazacyclododecane 1 4 7 10 tetraacetic acid conjugate
- IMMUNOGLOBULIN G1, ANTI-(MUCIN) (HUMAN-MUS MUSCULUS MONOCLONAL HPAM4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL HPAM4 .KAPPA.-CHAIN, DIMER, 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID CONJUGATE
- CAS registry numbers
- 1462876-11-4
- ChEMBL ID
- CHEMBL3301586
- FDA ingredient codes (UNII)
- 1D1F7UG35J
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- yttrium (90Y) clivatuzumab tetraxetan
- Type
- Antibody
- Drug name stem
- -mab; -mab; -xetan
Mechanisms of action
- Mechanism
- Mucin-5AC binding agent
- Action type
- BINDING_AGENT
- Target
- Mucin-5AC
- Protein identifier
- P98088
Open Targets mechanisms
- Mechanism
- Mucin-5AC binding agent
- Action type
- BINDING AGENT
- Target
- Mucin-5AC
Investigated indications
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition identifier
- EFO_0002618
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 3
- NCT00597129
- NCT00603863
- NCT01510561
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (4)
- A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
- Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
- Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
In development for (1)
- Exocrine pancreatic carcinoma Phase 1
Targets (1)
- MUC5AC Mucin-5AC binding agent